Kinpeygo 布地奈德缓释胶囊 budesonide

Drug Class

Locally-acting corticosteroid

Mechanism

Budesonide enteric capsule is designed to release budesonide in the distal ileum targeting Peyer's patches, suppressing Gd-IgA1 antibody production to halt IgAN pathogenesis.

Approved Indication

Treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression to reduce the loss of kidney function.

What This Means For Patients

Kinpeygo 布地奈德缓释胶囊 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2021) — Sources
• EMA — Approved (2022) — Sources
• NMPA — Approved (2023) — Sources

Pivotal Clinical Evidence

• NefIgArd — Lafayette et al., Lancet 2023 (NCT03643965) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215935s005lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo
• https://doi.org/10.1016/S0140-6736(23)01554-4